196 related articles for article (PubMed ID: 21397094)
1. Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device.
Donders GG; Berger J; Heuninckx H; Bellen G; Cornelis A
Contraception; 2011 Apr; 83(4):352-6. PubMed ID: 21397094
[TBL] [Abstract][Full Text] [Related]
2. Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS.
Rezk M; Sayyed T; Masood A; Dawood R
Eur J Contracept Reprod Health Care; 2017 Oct; 22(5):344-348. PubMed ID: 28849960
[TBL] [Abstract][Full Text] [Related]
3. Cytological evaluation and investigation of the vaginal flora of long-term users of the levonorgestrel-releasing intrauterine system (LNG-IUS).
Lessard T; Simões JA; Discacciati MG; Hidalgo M; Bahamondes L
Contraception; 2008 Jan; 77(1):30-3. PubMed ID: 18082663
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena®) on vaginal microbiota and Candida.
Donders GGG; Bellen G; Ruban K; Van Bulck B
J Med Microbiol; 2018 Mar; 67(3):308-313. PubMed ID: 29458551
[TBL] [Abstract][Full Text] [Related]
5. Do users of the intrauterine system (Mirena) have different genital symptoms and vaginal flora than users of the intrauterine contraceptive device?
Neale R; Knight I; Keane F
Int J STD AIDS; 2009 Jun; 20(6):423-4. PubMed ID: 19451330
[TBL] [Abstract][Full Text] [Related]
6. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
7. Reactional changes in short-term levonorgestrel-releasing intrauterine system (lng-ius) use.
Giraldo PC; Souza TC; Henrique GL; Monteiro I; Amaral R; Machado RB; Discacciati MG; Sanches JM
Rev Assoc Med Bras (1992); 2019 Jul; 65(6):857-863. PubMed ID: 31340317
[TBL] [Abstract][Full Text] [Related]
8. Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden.
Marions L; Lövkvist L; Taube A; Johansson M; Dalvik H; Øverlie I
Eur J Contracept Reprod Health Care; 2011 Apr; 16(2):126-34. PubMed ID: 21417562
[TBL] [Abstract][Full Text] [Related]
9. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
10. A pilot study on the acceptability of levonorgestrel-releasing intrauterine device by young, single, nulliparous Chinese females following surgical abortion.
Li CF; Lee SS; Pun TC
Contraception; 2004 Mar; 69(3):247-50. PubMed ID: 14969674
[TBL] [Abstract][Full Text] [Related]
11. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
Wildemeersch D; Janssens D; Vrijens M; Weyers S
Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
[TBL] [Abstract][Full Text] [Related]
12. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
13. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
14. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
Römer T; Linsberger D
Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
[TBL] [Abstract][Full Text] [Related]
15. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
Rose S; Chaudhari A; Peterson CM
Adv Drug Deliv Rev; 2009 Aug; 61(10):808-12. PubMed ID: 19445984
[TBL] [Abstract][Full Text] [Related]
16. Selection and performance of the levonorgestrel-releasing intrauterine system.
Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
[TBL] [Abstract][Full Text] [Related]
17. Use of the levonorgestrel-releasing intrauterine system: an Austrian perspective.
Concin H; Bösch H; Hintermüller P; Hohlweg T; Mursch-Edlmayr G; Pinnisch B; Schmidl-Amann S; Schulz-Greinwald G; Unterlerchner D; Wagner T; Mattle V; Wildt L; Fiala C
Curr Opin Obstet Gynecol; 2009 Nov; 21 Suppl 1():S1-9. PubMed ID: 20019650
[TBL] [Abstract][Full Text] [Related]
18. Impact of contraceptive initiation on vaginal microbiota.
Achilles SL; Austin MN; Meyn LA; Mhlanga F; Chirenje ZM; Hillier SL
Am J Obstet Gynecol; 2018 Jun; 218(6):622.e1-622.e10. PubMed ID: 29505773
[TBL] [Abstract][Full Text] [Related]
19. Vaginal microbiome changes with levonorgestrel intrauterine system placement.
Jacobson JC; Turok DK; Dermish AI; Nygaard IE; Settles ML
Contraception; 2014 Aug; 90(2):130-5. PubMed ID: 24835828
[TBL] [Abstract][Full Text] [Related]
20. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
Lukes AS; Reardon B; Arepally G
Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
